Edge
StocktwitsEarnings

Official STOCKTWITS Representative
$BCRX Q1 '25 Earnings Results & Recap
Biocryst Pharmaceuticals (BCRX) exceeded Q1 revenue estimates ($134M vs $127.79M est.) but EPS was flat vs a loss of ($0.08) estimate; full year revenue guidance was raised to $580M-$600M with the company expecting full year profitability, a year ahead of schedule. However, growth may slow in the coming quarters.3
7
